Company Focus
Chugai
Latest Chugai News
Biotechnology
National Health Service (NHS) England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with moderate hemophilia A with a severe bleeding phenotype who do not have factor VIII inhibitors. 2 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Chugai
Biotechnology
Danish biotech Genmab and US partner AbbVie have reported a decisive win in a Phase III study of their bispecific therapy Epkinly (epcoritamab) for follicular lymphoma, potentially paving the way for the first approved bispecific combination regimen in the second-line setting. 8 August 2025
Pharmaceutical
China-based Everest Medicines has secured full regulatory approval for Nefecon (budesonide) in Taiwan, marking the last of its Asian territories to grant the go-ahead for the immunoglobulin A nephropathy (IgAN) treatment. The decision finalizes the product’s rollout across the region and removes the conditions of its earlier accelerated approval. 7 August 2025
Pharmaceutical
USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi, in a deal worth up to $5.99 billion. 7 August 2025
Pharmaceutical
Germany’s Merck KGaA has reported second quarter earnings that missed analyst expectations. 7 August 2025
Pharmaceutical
Eli Lilly has posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand for its incretin portfolio. Non-GAAP earnings per share rose 61% to $6.31, with net income reaching $5.7 billion. 7 August 2025
Biotechnology
US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing from several high-profile investors as it seeks to transform how new biologic drugs are engineered. 7 August 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has granted accelerated approval for Ireland-headquartered Jazz Pharmaceuticals’ Modeyso (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. 7 August 2025
Biosimilars
The US Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of South Korean firm Celltrion’ Avtozma (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged two years and older. 6 August 2025
Pharmaceutical
Germany’s Bayer experienced a nightmare day’s trading Wednesday, with shares in the life sciences company more than 8% lower late on, as the firm presented detail on its second quarter 2025 financial results. 6 August 2025
Biotechnology
Intas Pharmaceuticals has introduced Hetronifly (serplulimab) in the Indian market. The therapy is the first PD-1 inhibitor globally approved for the treatment of extensive-stage small cell lung cancer (ES-SCLC), and its arrival in India follows a successful launch across Europe. 6 August 2025
Latest In Brief for Chugai
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim announced that Hernexeos (zongertinib tablets) has been recommended as a preferred subsequent therapy option for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with ERBB2 (HER2) mutations who received prior systemic therapy in the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for non-small cell lung cancer (Version 8), updated on August 15, 2025 16 August 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze